Our Impact on Rare Diseases
NCATS is the heart of rare diseases research at NIH. We speed the development of new rare disease treatments by focusing on approaches that can address more than one disease at a time.
Delivering Hope for Rare Diseases
Image of nine-year old Amber, who is part of gene therapy trial at the NIH Clinical Center and resident of The Children's Inn at NIH, with her parents and the CEO of The Children's Inn at NIH. (Daniel Soñé Photography)
There are more than 10,000 known rare diseases and only a few hundred have safe, effective treatments. In the United States, rare diseases affect about 1 in 10 people.
We are working hard to address the significant and often unmet needs of those affected by rare diseases. Through our research programs and other activities, we partner with patients, advocates, clinicians and researchers. Together, we have moved promising therapies into clinical trials, advanced therapeutic development tools and technologies, created widely used informational resources, and raised awareness of the rare disease public health challenge.
Our research priorities include shortening the time to diagnosis, spurring multiple treatments at a time, and making it easier and more efficient for scientists to discover and develop rare disease therapies. Because most rare diseases are genetic, we are especially focused on developing gene-targeted approaches for treating groups of rare diseases. We are also leveraging newer approaches, such as genetic analysis and machine learning, to help health care providers diagnose people with rare diseases and help people with rare diseases access the most current and reliable information.
Impact Stories
New FDA Designations May Jumpstart Gene Therapy Development
New FDA designations granted to NCATS for rare disease therapies provide financial incentives for companies to further develop treatments.
NCATS-Funded Rare Disease Researchers Provide Key Data, Help Build New Kidney Atlas
NEPTUNE’s research has helped us learn more about the biology of both rare and common kidney diseases. It has also led to better ways to diagnose and treat these conditions.
Rare Diseases Research Activities
We are addressing the public health challenges posed by rare diseases through a variety of collaborative research efforts.
Bespoke Gene Therapy Consortium
The Bespoke Gene Therapy Consortium (BGTC) focuses on developing platforms and standards to speed the development and delivery of gene therapies for rare diseases.
Therapeutics for Rare and Neglected Diseases (TRND)
The TRND program moves basic research discoveries in the lab closer to becoming new drugs.
Rare Diseases Clinical Research Network (RDCRN)
The RDCRN brings scientists together with rare disease organizations to study more than 200 rare diseases at sites across the country.
Rare Diseases Research News
New Path for a Gene Therapy Trial at NIH for a Rare Metabolic Disease
November 19, 2024 - NCATS News
- Bespoke Gene Therapy Consortium (BGTC)
- Our Impact on Clinical Trials
- Our Impact on Drug Discovery and Development
- Our Impact on Rare Diseases
- Platform Vector Gene Therapy (PaVe-GT)
Scientists at NCATS and other NIH institutes and centers are teaming up to advance a gene therapy treatment for MMA, a rare and potentially life-threatening genetic disorder.
Read ArticleEasing the Burden of Rare Diseases Through Translational Science
November 12, 2024 - NCATS News
- Our Impact on Rare Diseases
NCATS Director Joni Rutter discusses how NCATS is addressing scientific and operational roadblocks that slow progress for rare diseases research and treatments.
Sharing Science at the NIH Research Festival
October 22, 2024 - Grantee/Partner News
- Our Impact on Rare Diseases
- Platform Vector Gene Therapy (PaVe-GT)
New Drug Screening Funnel Could Speed New Therapies for Gaucher Disease, Parkinson’s
October 11, 2024 - NCATS News
- Assay Development and Screening Technology (ADST)
- Our Impact on Drug Discovery and Development
- Our Impact on Rare Diseases
A three-step drug-testing process created by NIH scientists and their partners could find new therapies faster for Gaucher disease and Parkinson’s disease.